Maintained strong financial position of $77.0 million in cash and marketable securities as of June 30, 2024, which are expected to support operations and the potential to achieve five clinical and regulatory milestones by late H1 2026
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
- Ovid Therapeutics appoints Banks as Chief Development Officer
- OVID Earnings this Week: How Will it Perform?
- Ovid Therapeutics Announces Leadership Transition and Consulting Deal
- Ovid Therapeutics to Present at Upcoming August Investor Conferences